International Clinical Trial: An Open-Label, Single-Arm, Single-Center Clinical Study of Disitamab Vedotin Combined with Toripalimab for the Treatment of Patients with HER2-Expressing High-Risk Non-Muscle-Invasive Bladder Cancer

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128773) titled 'An Open-Label, Single-Arm, Single-Center Clinical Study of Disitamab Vedotin Combined with Toripalimab for the Treatment of Patients with HER2-Expressing High-Risk Non-Muscle-Invasive Bladder Cancer' on July 25.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The Third Medical Centre, Chinese PLA General Hospital, Beijing, China

Condition: Bladder cancer

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026-08-01

Target Sample Size: Combined therapy group:50;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?pr...